Crescent Biopharma, Inc. (CBIO) Revenue History
Annual and quarterly revenue from 2011 to present
CBIO Revenue Over Time (2011–2025)
CBIO Revenue Growth History
3 of 10 years with positive growth- FY2011 revenue growth
- N/A
- FY2012 revenue growth
- +300.0%
- FY2013 revenue growth
- -73.8%
- FY2014 revenue growth
- +276.4%
- FY2015 revenue growth
- +33.6%
- FY2016 revenue growth
- -99.9%
- FY2017 revenue growth
- -100.0%
- FY2018 revenue growth
- N/A
- FY2019 revenue growth
- N/A
- FY2020 revenue growth
- N/A
- FY2021 revenue growth
- -88.6%
- FY2022 revenue growth
- -93.5%
- FY2023 revenue growth
- -86.7%
- FY2024 revenue growth
- -100.0%
- FY2025 revenue growth
- N/A
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $1.0M | — |
| Q4 2025 | $10.8M | — |
| Q3 2025 | $0 | — |
| Q2 2025 | $0 | — |
| Q1 2025 | $0 | — |
| Q4 2024 | $0 | -100.0% |
| Q3 2024 | $0 | — |
| Q2 2024 | $0 | — |
Multi-year avg. share of annual revenue by fiscal quarter
Revenue Breakdown (FY 2025)
CBIO's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
CBIO Revenue Analysis (2011–2025)
Current Revenue & Growth
As of June 12, 2026, Crescent Biopharma, Inc. (CBIO) generated trailing twelve-month (TTM) revenue of $11.9 million. The most recent quarter (Q1 2026) recorded $1.0 million in revenue, down 90.4% sequentially.
Historical Growth Trajectory
CBIO's 5-year compound annual growth rate (CAGR) stands at +1.3%, indicating moderate growth over time. The 3-year CAGR of +424.9% exceeds the 5-year average, indicating an acceleration in the most recent period. Crescent Biopharma, Inc.'s highest annual revenue of $20.1 million was recorded in 2015.
Revenue by Segment
CBIO's revenue is primarily driven by Reportable Segment (100%). With over half of revenue concentrated in Reportable Segment, the company has a focused business model while developing other growth vectors.
Peer Comparison
Compared to Healthcare sector peers — including RCUS (+67.4% YoY), KYMR (-12.6% YoY), and AGEN (+24.5% YoY). Compare CBIO vs RCUS →
CBIO Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
 CBIOCurrent | $12M | - | +1.3% | -1407.5% | |
 RCUS | $247M | +67.4% | +25.9% | -156.3% | |
 KYMR | $39M | -12.6% | +2.9% | -891.3% | |
 AGEN | $114M | +24.5% | +5.3% | -18.0% |
CBIO Historical Revenue Data (2011–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $10.8M | - | $10.8M | 100.0% | $-152,632,000 | -1407.5% |
| 2024 | $0 | -100.0% | $0 | - | $-49,897,519 | - |
| 2023 | $10K | -86.7% | $10K | 100.0% | $-39,275,293 | -392752.9% |
| 2022 | $75K | -93.5% | $75K | 100.0% | $-47,403,322 | -63204.4% |
| 2021 | $1.2M | -88.6% | $1.2M | 100.0% | $-63,447,205 | -5470.7% |
| 2020 | $10.2M | - | $0 | - | $-51,509,390 | -506.8% |
| 2019 | $0 | - | $-899,302 | - | $-61,389,000 | - |
| 2018 | $0 | - | $-275,123 | - | $-51,505,000 | - |
| 2017 | $0 | -100.0% | $-263,541 | - | $-33,932,280 | - |
| 2016 | $19K | -99.9% | $0 | - | $-31,913,485 | -172505.3% |
| 2015 | $20.1M | +33.6% | $20.1M | 100.0% | $-12,784,825 | -63.7% |
| 2014 | $15.0M | +276.4% | $15.0M | 100.0% | $-11,139,807 | -74.1% |
| 2013 | $4.0M | -73.8% | $4.0M | 100.0% | $-10,606,480 | -265.7% |
| 2012 | $15.3M | +300.0% | $15.3M | 100.0% | $3.6M | 23.8% |
| 2011 | $3.8M | - | $0 | - | $-6,084,802 | -159.5% |
What if you invested $1,000 in CBIO back in 2011?
Total return with dividends reinvested · 15+ years of data
Calculate ReturnsHow much would $100/month in CBIO be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs CBIO Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCBIO vs LLY — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs Eli Lilly and Company.
Compare NowCBIO — Frequently Asked Questions
Quick answers to the most common questions about buying CBIO stock.
Is CBIO's revenue growth accelerating or slowing?
CBIO TTM revenue: $12M. YoY growth: N/A. 5-year CAGR: +1.3%.
What is CBIO's revenue history from 2011 to 2026?
Crescent Biopharma, Inc. (CBIO) revenue history spans 2011 to 2026. TTM revenue as of 2026 is $12M, growing at N/A YoY. The 5-year CAGR is +1.3%. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is CBIO's long-term revenue growth rate (CAGR)?
Crescent Biopharma, Inc.'s 5-year revenue CAGR of +1.3% reflects the variable nature of its business expansion. As of 2026, the current YoY growth rate of N/A is in line with this long-term average. CAGR is the most reliable measure of sustained revenue momentum for CBIO.
Why does CBIO's quarterly revenue fluctuate?
CBIO quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. Crescent Biopharma, Inc.'s revenue data from 2011 to 2026 shows full historical quarterly detail on this page.
How is CBIO's revenue distributed by segment?
CBIO reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does CBIO's revenue compare to industry peers?
Crescent Biopharma, Inc. (CBIO) with TTM revenue of $12M and N/A YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.